CN104306941B - A kind of medicine for treating Non-erosive gastroesophageal reflux disease and its application - Google Patents
A kind of medicine for treating Non-erosive gastroesophageal reflux disease and its application Download PDFInfo
- Publication number
- CN104306941B CN104306941B CN201410594964.3A CN201410594964A CN104306941B CN 104306941 B CN104306941 B CN 104306941B CN 201410594964 A CN201410594964 A CN 201410594964A CN 104306941 B CN104306941 B CN 104306941B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- gastroesophageal reflux
- erosive gastroesophageal
- reflux disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of medicine for treating Non-erosive gastroesophageal reflux disease, it is made up of the bulk drug of following parts by weight：10 ~ 14 parts of radix bupleuri, 10 ~ 14 parts of Fructus Aurantii, 2 ~ 4 parts of the coptis, 2 ~ 4 parts of evodia rutaecarpa, 10 ~ 14 parts of gold boiling grass, 13 ~ 17 parts of raddle, 4 ~ 8 parts of peninjau gardenia, 10 ~ 14 parts of corydalis tuber, 7 ~ 11 parts of Fructus meliae toosendan, forge 27 ~ 33 parts of corrugation, 2 ~ 4 parts of ginger, 4 ~ 8 parts of radix glycyrrhizae.The invention further relates to said medicine to prepare the application in treating Non-erosive gastroesophageal reflux medicine.The medicine of the present invention has the effect of dispersing stagnated hepatoqi, harmonizing stomach and lowering adverse Qi for the interpretation of the cause, onset and process of an illness " ascending or descending movement of vital Qi is lacked of proper care, stomach Qi upward reversal " of Non-erosive gastroesophageal reflux disease.Test result indicates that medicine of the present invention is not only efficient to be higher than existing market common drug, and recurrence rate is low after drug withdrawal, is worthy to be popularized.
Description
Technical field
It is in specifically the present invention relates to a kind of medicine for treating Non-erosive gastroesophageal reflux disease and its application
Herbal medicine is Chinese patent drug prepared by raw material.
Background technology
GERD（GERD）It is clinical common disease of digestive system, is due to lower esophageal sphincter LES work(
Can imbalance, or the Closure insufficiency of pyloric sphincter, cause stomach and（Or）The duodenal non-transient ground reflux of content
Enter oesophagus, cause the lesions such as hyperemia, oedema, erosion and the fibrosis of Esophageal Mucosa by long-term, stimulation repeatedly.GERD bags
Include Non-erosive gastroesophageal reflux disease（NERD）, erosive esophagitis（RE）With barrett oesophaguses.Possess GERD symptoms and without interior
Under mirror mucosa lesions for Non-erosive gastroesophageal reflux disease, and with Esophageal Mucosa in a organized way Pathological lesions change be referred to as
Erosive esophagitis.There is investigation to show Beijing, the esophageal reflux symptom incidence of Shanghai two places is up to 8.97%.
GERD is relevant with many factors, including Gender, age, race, Hp Infection Status, food, constitutional index, suction
Cigarette, drink, inherent cause etc..The gastroesophageal reflux related symptoms epidemiology survey that Guo Hui equalitys are carried out is drawn a conclusion, stomach food
Pipe reflux is related indication, and to have clear and definite inducement person be 61.3%, and common inducement is：Diet（Pungent, greasy food etc.）, it is raw
Gas, fatigue, anxiety etc..Hazards：Reflux symptom frequent difficult defecation, often feed satiety, often feed it is pungent, greasy
Incidence in food crowd is apparently higher than general population（P<0.05）（Guo Huiping, Pan Guozong, wait Beijing adult's stomach oesophagus anti-
Stream related symptoms epidemiology survey, gastroenterology and liver and bladder disease magazine, 1997,6:122-126）；Watanabe Y etc. are ground
Think after studying carefully the Japanese man of one group of butter GERD, smoking, the generation drunk with GERD are closely related.
（Watanabe Y,Fujiwara Y,et al.Cigarette smoking and alcoholconsumption
associated with gastro-oesophageal reflux disease in Japanese man.Scand
JGastroenterol.2003 Aug;38(8):807-811）.
For the sick treatment at present using PPI proton pump inhibitors as Main Means.Proton pump inhibitor PPIs is can
Specific and noncompetitive acts on H+/K+-ATP enzymes, and it has very strong to basic hydrochloric acid in gastric juice and post-stimulatory gastric acid secretion
Inhibitory action, gastric juice is set to become neutral, even if reflux occurs again, neutral gastric juice also no longer produces infringement to oesophagus, uses
PPIS treatment GERDs have the function that the advantages of rapid-action strong, but do not solve the problems, such as reflux fundamentally, one
Denier withdrawal symptom recurs at once, makes the sensitiveness that can not only influence medicine for a long time, and patient have obvious headache, diarrhoea,
The symptoms such as Nausea and vomiting, myalgia, fash.Non-erosive gastroesophageal reflux disease accounts for the 70% of GRED, its incidence of disease, recurrence rate
Height, to proton pump inhibitor（PPI）Therapeutic response is poor, has a strong impact on patients ' life quality for a long time, and disease control it is costly.
The categories such as NRED category traditional Chinese medicine " acid regurgitation " " noisy " " epigastric pain " " gastric disorder causing nausea " " dysphagic " " feeling of stuffiness in chest ".Sick position is in stomach and food
Pipe, the lifting of catharsis, taste with liver have close relationship.NRED can be cured temporarily after treatment, but due to causing stomach to be eaten
The Fundamentals of pipe reflux still suffer from, so easily recurrence.How to prevent the palindromia that effects a permanent cure, turn into the maximum difficult point of this disease.China
Traditional Chinese medicine and pharmacy can the 22nd national the spleen-stomach diseases seminar and the spleen-stomach diseases diagnosis and treatment new development study class paper remittance in 2010
Volume discloses《Logical drop and stomach treatment by Chinese herbs 178 clinical observations of old age GERD》, treatment GERD medicine is basic
Form as HERBA INULAE, raddle, radix bupleuri, corydalis tuber, Fructus Aurantii, the coptis, evodia rutaecarpa, peninjau gardenia, radix pseudostellariae, if see sour regurgitation it is more than,
It is heartburn repeatedly, then plus cuttle bone, forge corrugation, spiral shell etc.；If symptoms include heating is frequent, gastral cavilty turgor, then add with caulis perllae, Buddhist
Hand, Pericarpium Citri, rascal, dried orange peel, the shell of areca nut, fructus amomi, cool benevolence etc.；If symptoms include constipation, plus with Fructus Trichosanthis, coffee senna etc..
It treats GRED positive effects, but need to need to increase and decrease medicine on square foundation for different pathological factor can for said medicine
Reach the effect of preferable, add diagnosis and treatment on difficulty, and the medicine to NRED treat after recurrence still not
It is clear.Therefore need badly it is a kind of controlled without differentiation of symptoms and signs for classification of syndrome opinion, medicine evident in efficacy while low recurrence rate treatment NRED, but mesh
It is preceding to be had not been reported on this kind of medicine.
The content of the invention
The purpose of the present invention is to be directed to deficiency of the prior art, there is provided it is a kind of treat Non-erosive gastroesophageal reflux disease
Medicine.
Another purpose of the present invention is to provide the purposes of said medicine.
To achieve the above object, the present invention adopts the technical scheme that：
A kind of medicine for treating Non-erosive gastroesophageal reflux disease, it is made up of the bulk drug of following parts by weight：Radix bupleuri
10 ~ 14 parts, 10 ~ 14 parts of Fructus Aurantii, 2 ~ 4 parts of the coptis, 2 ~ 4 parts of evodia rutaecarpa, gold boiling grass 10 ~ 14 parts, 13 ~ 17 parts of raddle, peninjau gardenia 4
~ 8 parts, 10 ~ 14 parts of corydalis tuber, 7 ~ 11 parts of Fructus meliae toosendan, forge 27 ~ 33 parts of corrugation, 2 ~ 4 parts of ginger, 4 ~ 8 parts of radix glycyrrhizae.
Described medicine is made up of the bulk drug of following parts by weight：11 ~ 13 parts of radix bupleuri, 11 ~ 13 parts of Fructus Aurantii, the coptis 2 ~ 4
Part, 2 ~ 4 parts of evodia rutaecarpa, gold boiling grass 11 ~ 13 parts, 14 ~ 16 parts of raddle, 5 ~ 7 parts of peninjau gardenia, 11 ~ 13 parts of corydalis tuber, Fructus meliae toosendan 8 ~
10 parts, forge 29 ~ 31 parts of corrugation, 2 ~ 4 parts of ginger, 5 ~ 7 parts of radix glycyrrhizae.
Described medicine is made up of the bulk drug of following parts by weight：12 parts of radix bupleuri, 12 parts of Fructus Aurantii, 3 parts of the coptis, evodia rutaecarpa
3 parts, gold boiling grass 12 parts, 15 parts of raddle, 6 parts of peninjau gardenia, 12 parts of corydalis tuber, 9 parts of Fructus meliae toosendan, forge 30 parts of corrugation, 3 parts of ginger,
6 parts of radix glycyrrhizae.
Described drug agents are capsule, particle, tablet, oral liquid, mixture or syrup.
To realize above-mentioned second purpose, the present invention adopts the technical scheme that：
As above application of any described medicine in the medicine for preparing treatment Non-erosive gastroesophageal reflux disease.
Radix bupleuri cold nature, slight bitter, master is soothing the liver, and the sharp liver and gall of energy, the solution obstruction of the circulation of vital energy, Fructus Aurantii is bitterly, is slightly cold, pungent to open bitter drop, is longer than
Regulating the flow of QI to ease the stomach, radix bupleuri, Fructus Aurantii are monarch drug in a prescription；The coptis, evodia rutaecarpa simultaneously using both cold and hot drugs, fall fire is opened strongly fragrant；HERBA INULAE is worked hard salty, tepor, enters lung
Stomach, raddle bitter cold, matter resedimentation, there is the effect of lowering the adverse flow of QI, be apt to the stomach Qi of drop superinverse, HERBA INULAE, raddle one cold one is warm,
Town liver drop is inverse, and two pairs of medicines nurse one's health liver and gall taste mechanism of qi for ministerial drug principal drug assistance altogether, altogether long memorial liver and qi, the effect of harmonizing stomach and lowering adverse Qi；Prolong recklessly
Rope, Fructus meliae toosendan, peninjau gardenia three share, and fever and chills are mutually made, and common assistant helps the monarch and his subjects to unclog and readjust irritability, sending down abnormally ascending and stomach.Forge corrugation, ginger,
It is all to make medicine that radix glycyrrhizae, which shares, can both be strengthened the spleen and stomach, again can coordinating the drug actions of a prescription.All medicines share, suitable, tonification and purgation in combination is lifted, so as to reach
To dispersing stagnated hepatoqi, the effect of harmonizing stomach and lowering adverse Qi.
The invention has the advantages that：
1st, medicine of the invention is directed to the interpretation of the cause, onset and process of an illness " ascending or descending movement of vital Qi is lacked of proper care, stomach Qi upward reversal " of Non-erosive gastroesophageal reflux disease,
The effect of with dispersing stagnated hepatoqi, harmonizing stomach and lowering adverse Qi.
2nd, medicine of the invention improves obvious for the clinical symptoms of Non-erosive esophageal reflux disease, have it is efficient it is high,
The characteristics of recurrence rate is low.
3rd, medicine of the invention is made up of pure Chinese medicine, has no toxic side effect, and can be made into capsule, particle, tablet, oral liquid,
Mixture or syrup, it is easy to be accepted by patients.
Embodiment
Embodiment provided by the invention is elaborated below.
Embodiment 1 treats the preparation of Non-erosive gastroesophageal reflux medicine（One）
10 parts of radix bupleuri, 14 parts of Fructus Aurantii, 2 parts of the coptis, 4 parts of evodia rutaecarpa, gold boiling grass 10 parts, 17 parts of raddle, 4 parts of peninjau gardenia,
14 parts of corydalis tuber, 7 parts of Fructus meliae toosendan, forge 33 parts of corrugation, 2 parts of ginger, 8 parts of radix glycyrrhizae, conventional method decoction.
Embodiment 2 treats the preparation of Non-erosive gastroesophageal reflux medicine（Two）
14 parts of radix bupleuri, 10 parts of Fructus Aurantii, 4 parts of the coptis, 2 parts of evodia rutaecarpa, gold boiling grass 14 parts, 13 parts of raddle, 8 parts of peninjau gardenia,
10 parts of corydalis tuber, 11 parts of Fructus meliae toosendan, forge 27 parts of corrugation, 4 parts of ginger, 4 parts of radix glycyrrhizae, conventional method decoction.
Embodiment 3 treats the preparation of Non-erosive gastroesophageal reflux medicine（Three）
11 parts of radix bupleuri, 13 parts of Fructus Aurantii, 2 parts of the coptis, 4 parts of evodia rutaecarpa, gold boiling grass 11 parts, 16 parts of raddle, 5 parts of peninjau gardenia,
13 parts of corydalis tuber, 8 parts of Fructus meliae toosendan, forge 32 parts of corrugation, 2 parts of ginger, 7 parts of radix glycyrrhizae, conventional method decoction.
Embodiment 4 treats the preparation of Non-erosive gastroesophageal reflux medicine（Four）
13 parts of radix bupleuri, 11 parts of Fructus Aurantii, 4 parts of the coptis, 2 parts of evodia rutaecarpa, gold boiling grass 13 parts, 14 parts of raddle, 7 parts of peninjau gardenia,
11 parts of corydalis tuber, 10 parts of Fructus meliae toosendan, forge 28 parts of corrugation, 3 parts of ginger, 5 parts of radix glycyrrhizae, conventional method decoction.
Embodiment 5 treats the preparation of Non-erosive gastroesophageal reflux medicine（Five）
11 parts of radix bupleuri, 11 parts of Fructus Aurantii, 3 parts of the coptis, 3 parts of evodia rutaecarpa, gold boiling grass 13 parts, 16 parts of raddle, 5 parts of peninjau gardenia,
11 parts of corydalis tuber, 10 parts of Fructus meliae toosendan, forge 31 parts of corrugation, 3 parts of ginger, 6 parts of radix glycyrrhizae, conventional method decoction.
Embodiment 6 treats the preparation of Non-erosive gastroesophageal reflux medicine（Six）
13 parts of radix bupleuri, 13 parts of Fructus Aurantii, 2 parts of the coptis, 3 parts of evodia rutaecarpa, gold boiling grass 11 parts, 14 parts of raddle, 7 parts of peninjau gardenia,
12 parts of corydalis tuber, 9 parts of Fructus meliae toosendan, forge 31 parts of corrugation, 2 parts of ginger, 5 parts of radix glycyrrhizae, conventional method decoction.
Embodiment 7 treats the preparation of Non-erosive gastroesophageal reflux medicine（Seven）
12 parts of radix bupleuri, 12 parts of Fructus Aurantii, 3 parts of the coptis, 4 parts of evodia rutaecarpa, gold boiling grass 11 parts, 14 parts of raddle, 7 parts of peninjau gardenia,
12 parts of corydalis tuber, 9 parts of Fructus meliae toosendan, forge 31 parts of corrugation, 2 parts of ginger, 6 parts of radix glycyrrhizae, conventional method decoction.
Embodiment 8 treats the preparation of Non-erosive gastroesophageal reflux medicine（Eight）
12 parts of radix bupleuri, 12 parts of Fructus Aurantii, 3 parts of the coptis, 3 parts of evodia rutaecarpa, gold boiling grass 12 parts, 15 parts of raddle, 6 parts of peninjau gardenia,
12 parts of corydalis tuber, 9 parts of Fructus meliae toosendan, forge 30 parts of corrugation, 3 parts of ginger, 6 parts of radix glycyrrhizae, conventional method decoction.
It should be noted that it is the conventional preparation method of traditional Chinese herbal decoction that the conventional method described in embodiment 1-8, which decocts, will
Described bulk drug adds water to cook into decoction.
Embodiment 9 treats the preparation of Non-erosive gastroesophageal reflux medicine tablets/capsules
Any described medicines of Example 1-8, add 8-12 times to measure water, decoct 1-3 hours, filter out concoction.Again plus 10 times
Water is measured, 1.5-2.5 hours is decocted, filters out concoction, merge secondary decocting liquid, is stood, leaching supernatant, concentration, lets cool, adds concentrate
2.5 times of amount alcohol, stir precipitates overnight.Supernatant is taken, is concentrated into thick medicinal extract；Pharmaceutical aids is added, vacuum drying, crushes system
Grain, tabletted or filling are encapsulated.
Embodiment 10 treats the preparation of Non-erosive gastroesophageal reflux medicine particle
Any described medicines of Example 1-8, add 8-10 times to measure water, decoct 2.5-3.5 hours, filter out concoction.Again plus
10 times of amount water, decoct 2 hours, filter out concoction, merge secondary decocting liquid, stand, leaching supernatant, concentration, let cool, add concentrate 2
Amount alcohol again, stir precipitates overnight.Supernatant is taken, is concentrated into thick medicinal extract；Add appropriate pharmaceutical aids, pelletize, dry, whole grain, obtain
20g particles, dispense 10g/ bags.
Embodiment 11 treats the preparation of Non-erosive gastroesophageal reflux medicine mixture/oral liquid/syrup
Any described medicines of Example 1-8, add 8-10 times to measure water, decoct 3 hours, filter out concoction.Again plus 8 times are measured
Water, decoct 2 hours, filter out concoction, merge secondary decocting liquid, stand, leaching supernatant, concentration, let cool, add 2 times of amount wine of concentrate
Essence, stir precipitates overnight.Supernatant is taken, is concentrated into thick medicinal extract；Add appropriate pharmaceutical aids, mixture, oral liquid or syrup is made.
Embodiment 12
1 data and method
1.1 general information
Collect -2014 Nian9Yue Shanghai University of Chinese Medicine Affiliated Yueyang Integrated Traditional and Western Medicine Hospital GERDs in 2012
Training and Gastroenterology dept.'s consulting patients in out-patient department 150（Age 18-75 year）, treatment group, control group are divided into using random digits table
One and control group two each 50, man 20, female 30 wherein in treatment group；Average age M=48.35 year old, average course of disease M=3.24
Year；Man 18, female 32 in control group one；Average age M=49.53 year old, average course of disease M=3.22 year；Man 19 in control group two
Example, female 31；Average age M=50.14 year old, average course of disease M=3.39 year.Three groups of ordinary circumstance comparing differences are not statistically significant
（P>0.05）, there is comparativity.
1.2 case selection
1.2.1 inclusive criteria
（1）With reference to GERD National Consensus expert group of China of disease for digest branch of Chinese Medical Association《Chinese stomach oesophagus
Reflux disease National Consensus（In October, 2006 Sanya）》In relevant standard；
（2）In the presence of typical gastroesophageal reflux symptom, at least continue more than 3 months, or be associated with outside oesophagus and show, stomach food
Pipe reflux disease questionnaire（RDQ）Scoring>12 points；
（3）Gastrocopy is negative；
（4）Proton pump inhibitor is tested（PPI）It is positive.
1.2.2 exclusion standard
（1）Endoscopy has taste-blindness rate（No matter active stage or resting stage）Or erosive duodenitis person；
（2）With tumor in digestive tract person；
（3）There is upper gastrointestinal operation person.
1.3 treatment method
The medicine that treatment group is prepared using embodiment 12, it is 0.31g/mL containing crude drug amount to decoct to concentration, one portion per day, is decocted
Juice is swallowed, 100mL/ times, and once a dose sooner or later.Control group one uses HERBA INULAE 12g, raddle 15g, coptis 3g, evodia rutaecarpa 3g,
Radix bupleuri 6g, Fructus Aurantii 12g, peninjau gardenia 9g, radix scutellariae 15g, rhizoma cyperi 12g, cloves 3g, corydalis tuber 10g, Fructus meliae toosendan 10g, radix glycyrrhizae 6g, decoct
It is 0.31g/mL containing crude drug amount to boil to concentration, and one portion per day, pan-fried juice is swallowed, 100mL/ times, and once a dose sooner or later.Control group two makes
Use Omeprazole（Pharmaceutical Co Ltd, Changzhou Pharmaceutical Factory No.4, lot number：20110225）Each 20mg, twice daily, 15 ~ 30 min before meals
Orally.
1.4 observational technique
1.4.1 Clinical symptom and sign
Pretherapy and post-treatment reference《Chinese GERD National Consensus》And《New Chinese medicine guideline of clinical investigations》In
Relevant standard, using integration method observe cardinal symptom sign situation.Including pain or uncomfortable, anti-after heartburn, pantothenic acid, burning breastbone
Stomach, pharyngeal uncomfortable or pain, dysphagia, heating, big belly, epigastric pain, be divided into without, it is light, in, weigh 4 grades, respectively 0 point, 1
Divide, 2 points, 3 points.Medication 8 weeks is a course for the treatment of, and medication carries out therapeutic evaluation after 8 weeks.
1.4.2 clinical efficacy
Reference《New Chinese medicine guideline of clinical investigations》In relevant standard determination clinical efficacy.
（1）Recovery from illness：Clinical symptom and sign disappears, and integration reduces >=95%；
（2）It is effective：Clinical symptom and sign disappears substantially（Though even have symptom but disappear quickly）, integration reduction 70% ~ 94%；
（3）Effectively：Clinical symptom and sign does not disappear, but mitigates than before, and integration reduces 30% ~ 69%；
（4）It is invalid：Clinical symptom and sign does not disappear, and degree does not mitigate, and integration reduces ＜ 30%.
1.5 Evaluation of long-term standards
Recurrence：Each follow-up 1 time when being discontinued 4 weeks and 8 weeks, the GERD questionnaire filled in during follow-up（RDQ）Integration>Treat
At the end of journey（8 weeks）RDQ is integrated, and >=12；Do not recur：Each follow-up 1 time during drug withdrawal 14d and 28d, the RDQ products filled in during follow-up
At the end of dividing compared with the course for the treatment of（8 weeks）RGD integrations do not increase.
1.6 statistical method
Observed data carries out statistical analysis using the softwares of SPSS 18.0.Measurement data with± s represents that statistics is adopted
Examined with t, the variance analysis using repeated measurement data data is compared between group；Ranked data are examined using Mann-Whitney.
With P<0.05 is that difference is statistically significant.
2. result
2.1 total effective rates compare
Treatment group fully recovers 7, effective 18, effective 22, invalid 3；Control group one is fully recovered 4, effective 15, effectively
23, invalid 8；Control group two is fully recovered 5, effective 15, effective 23, invalid 7.Treatment group's total effective rate is 94.0%,
The total effective rate of control group one is 84.0%, and the total effective rate of control group two is 86.0%, through three groups of Chi-square Test compare between any two without
Significant difference（P>0.05）.
The frequency that 2.2 each symptoms occur
Evaluated using gastroesophageal reflux disorders shape marking scales to being integrated before and after each symptom treatment, integration evaluation is such as
Shown in table 1.
Table 1
。
By to pain after heartburn, pantothenic acid, breastbone or discomfort, gastric disorder causing nausea, pharyngeal uncomfortable or pain, dysphagia, heating, upper abdomen
Totally nine common symptoms are counted swollen, epigastric pain, wherein four kinds of symptoms of occurrence frequency highest are heartburn, pantothenic acid, throat not
Suitable, heating, frequency is respectively 81%, 78%, 77%, 73%；Dysphagia occurrence frequency is minimum, is 7%.
2.3 each symptoms improve situation
A pair for the treatment of group is heartburn, pain or discomfort, gastric disorder causing nausea, dysphagia, heating, big belly, upper abdomen pain after pantothenic acid, breastbone
Shape improves significantly（P<0.05）, and unobvious are improved to pharyngeal uncomfortable pain（P>0.05）, it is shown in Table 2；Control group burns for a pair
Pain or discomfort, gastric disorder causing nausea, heating, big belly, epigastric pain improve significantly after the heart, pantothenic acid, breastbone（P<0.05）, and to it is pharyngeal not
Suitable pain, dysphagia improve unobvious（P>0.05）, it is shown in Table 3；Control group two is to pain after heartburn, pantothenic acid, breastbone or uncomfortable, pharynx
Portion is uncomfortable or pain, big belly, upper abdomen pain symptom improve significantly（P<0.05）, and gastric disorder causing nausea, dysphagia, heating are improved
Unobvious（P>0.05）, it is shown in Table 4.
Each symptom score compares before and after the treatment group of table 2（±s）
。
Each symptom score compares the control group one of table 3 before and after treatment（±s）
。
Each symptom score compares the control group two of table 4 before and after treatment（±s）
。
2.4 end-of-dose failure rates
Follow-up after being discontinued 4 weeks, treatment group, control group one, the recurrence rate of control group two are respectively 10.3%, 22.6%, 52.6%.
Follow-up after being discontinued 8 weeks, treatment group, control group one, the recurrence rate of control group two are respectively 13.6%, 32.2%, 65.9%.Wherein treat
Group, control group one, the recurrence rate of control group two are compared two-by-two has comparativity（P<0.05）.
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, on the premise of the inventive method is not departed from, can also make some improvement and supplement, and these are improved and supplement also should be regarded as
Protection scope of the present invention.
Claims (2)
1. a kind of medicine for treating Non-erosive gastroesophageal reflux disease, it is characterised in that it is by the bulk drug of following parts by weight
It is made：12 parts of radix bupleuri, 12 parts of Fructus Aurantii, 3 parts of the coptis, 3 parts of evodia rutaecarpa, gold boil careless 12 parts, 15 parts of raddle, 6 parts of peninjau gardenia, prolonged recklessly
12 parts of rope, 9 parts of Fructus meliae toosendan, forge 30 parts of corrugation, 3 parts of ginger, 6 parts of radix glycyrrhizae；The formulation of the medicine is capsule, particle, tablet, mouth
Take liquid, mixture or syrup.
2. application of the medicine in the medicine for preparing treatment Non-erosive gastroesophageal reflux disease described in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410594964.3A CN104306941B (en) | 2014-10-30 | 2014-10-30 | A kind of medicine for treating Non-erosive gastroesophageal reflux disease and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410594964.3A CN104306941B (en) | 2014-10-30 | 2014-10-30 | A kind of medicine for treating Non-erosive gastroesophageal reflux disease and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104306941A CN104306941A (en) | 2015-01-28 |
| CN104306941B true CN104306941B (en) | 2018-01-02 |
Family
ID=52362350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410594964.3A Active CN104306941B (en) | 2014-10-30 | 2014-10-30 | A kind of medicine for treating Non-erosive gastroesophageal reflux disease and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104306941B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906554B (en) * | 2015-07-16 | 2018-03-02 | 上海中医药大学附属岳阳中西医结合医院 | A kind of Chinese medicine composition for treating refractory gastroesophageal reflux disease and its application |
| CN105213991B (en) * | 2015-10-23 | 2020-06-12 | 王丽媛 | Traditional Chinese medicine composition for treating gastroesophageal reflux disease |
| CN115282256B (en) * | 2022-09-16 | 2023-08-22 | 上海中医药大学附属岳阳中西医结合医院 | NERD disease and syndrome combination model and construction method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209340A (en) * | 2006-12-25 | 2008-07-02 | 上海中医药大学附属岳阳中西医结合医院 | Chinese medicinal composition for treating gastroesophageal reflux disease |
| WO2012040915A1 (en) * | 2010-09-29 | 2012-04-05 | 深圳市齐旺投资有限公司 | Chinese medicinal composition for treating stomach pain of hepatogastric stagnated heat type, preparing method thereof |
-
2014
- 2014-10-30 CN CN201410594964.3A patent/CN104306941B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209340A (en) * | 2006-12-25 | 2008-07-02 | 上海中医药大学附属岳阳中西医结合医院 | Chinese medicinal composition for treating gastroesophageal reflux disease |
| WO2012040915A1 (en) * | 2010-09-29 | 2012-04-05 | 深圳市齐旺投资有限公司 | Chinese medicinal composition for treating stomach pain of hepatogastric stagnated heat type, preparing method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 疏肝和胃方治疗非糜烂性胃食管反流病临床观察;程艳梅等;《上海中医药杂志》;20131231;第47卷(第6期);第48-49页尤其是第48页1.3治疗方法中1.3.1中药组 * |
| 通降和胃方治疗胃食管反流性咳嗽60例;刘春芳等;《环球中医药》;20130731;第6卷(第7期);第539-541页，尤其是539-540页1.4治疗方法，第541页左栏第12-22行 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104306941A (en) | 2015-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100518810C (en) | Chinese medicinal composition for treating gastroesophageal reflux disease | |
| CN102166284B (en) | Medicine for treating reflux esophagitis and preparation method thereof | |
| CN102284049B (en) | A kind ofly alleviate compound Chinese medicinal preparation of chemicotherapy toxicity and uses thereof | |
| WO2000006181A1 (en) | A medicament for treating recurrent ulcer of mouth and behcet's syndrome | |
| CN103751739A (en) | Traditional Chinese medicine composition for treating chronic gastritis, application of composition in preparation of medicine for treating chronic gastritis, and preparation method of composition | |
| CN108743892A (en) | The preparation method and applications of " Shengyang Yiwei Decoction " side's Chinese medical extract | |
| CN101209340B (en) | Chinese medicinal composition for treating gastroesophageal reflux disease | |
| CN104306941B (en) | A kind of medicine for treating Non-erosive gastroesophageal reflux disease and its application | |
| CN101780252A (en) | Traditional Chinese medicine compound for treating intestinal obstruction and preparation method thereof | |
| CN102813711B (en) | Medicine for treating gastroesophageal reflux disease and application of medicine | |
| CN104906554B (en) | A kind of Chinese medicine composition for treating refractory gastroesophageal reflux disease and its application | |
| CN104721256A (en) | Anwei Yang extract as well as preparation method and medical application thereof | |
| CN103599367A (en) | Capsule for gastrointestinal ulcer and preparation technology thereof | |
| CN105749127A (en) | Pharmaceutic preparation for treating stomach cancer and application thereof | |
| CN105412822A (en) | Spleen-strengthening blood stasis-removing Chinese herbal compound composition and application thereof | |
| CN110279763A (en) | The pharmaceutical composition and preparation and application and preparation for treating gastroesophageal reflux disease | |
| CN105148151A (en) | Medicine for treating spleen and stomach deficiency-cold type reflux esophagitis and preparation method | |
| CN104784650A (en) | Pharmaceutical preparation for clinical nursing of gastric ulcer | |
| CN104491637B (en) | It is a kind of to treat compound composite medicament of cough after common cold and preparation method and application | |
| CN102512643B (en) | Traditional Chinese medicine composition for treating GERD (gastroesophageal reflux disease) and FGID (functional gastrointestinal disorders) | |
| CN116747274B (en) | Traditional Chinese medicine composition and preparation for treating gastroesophageal reflux disease with syndrome of liver-stomach stagnation heat and application of traditional Chinese medicine composition and preparation | |
| CN113769040B (en) | Granule for regulating qi and harmonizing stomach | |
| CN115282256B (en) | NERD disease and syndrome combination model and construction method and application thereof | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN104958729A (en) | Pharmaceutical composition for preventing recurrence and metastasis of gastrointestinal tumors, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |